No Data
Mabpharm (HKG:2181) Adds HK$1.2b to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 34%
There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 114% Price Jump
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Mabpharm's Infliximab Drug Receives Approval From Pakistan's Drug Regulator
MABPHARM-B (02181.HK): The Indonesian Food and Drug Authority has approved the marketing authorization for the core product CMAB008 (infliximab injection).
On December 27, Gelonghui announced that MABPHARM-B (02181.HK) has recently obtained approval from the Indonesian Food and Drug Administration for the marketing license of its core product, the self-developed recombinant anti-tumor necrosis factor α ("TNFα") human-mouse chimeric monoclonal antibody CMAB008 (infliximab for injection), for the treatment of: (i) adult ulcerative colitis; (ii) ankylosing spondylitis; (iii) rheumatoid arthritis; (iv) Crohn's disease in adults and children over 6 years old; (v) fistulizing Crohn's disease; and (vi) psoriasis.
Express News | Mabpharm - Approval From Indonesian National Agency of Drug and Food Control on Marketing Authorization of Cmab008 (Infliximab for Injection)
Some Mabpharm Limited (HKG:2181) Shareholders Look For Exit As Shares Take 41% Pounding
